Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 10/20 | 0.67 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541690 | 0.89 | QPCT (0.54) | QPCTP2RY14NPC1RAB9AKDM4E | |
| SCHEMBL2536231 | 0.86 | QPCT (0.67) | QPCTP2RY14SMN1; SMN2IP6K1 | |
| SCHEMBL2539376 | 0.86 | QPCT (0.67) | QPCTP2RY14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2541359 | 0.85 | QPCT (0.69) | QPCTP2RY14NPC1RAB9AKDM4E | |
| SCHEMBL24821371 | 0.84 | ADRA2A (0.51) | QPCTP2RY14RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL2542456 | 0.81 | CYP3A4 (0.61) | QPCTP2RY14KDM4EALDH1A1MAPT | |
| SCHEMBL14550820 | 0.81 | IP6K1 (0.77) | QPCTNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL2540163 | 0.80 | QPCT (0.71) | QPCTRAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL12633978 | 0.79 | QPCT (0.53) | QPCTP2RY14KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL12257241 | 0.79 | ADRA2A (0.54) | QPCTP2RY14KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541596-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2560953-A2 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131748-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110262388-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262388-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | QPCT 2/4885P2RY14 2607/4885NPC1 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.